findmyKOL
Clinical trialNCT03770260CompletedPhase 1Interventional

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

SponsorNational Cancer Institute (NCI)Enrollment8Recurrent Multiple MyelomaRefractory Multiple Myeloma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase Ib trial studies side effects and best dose of pevonedistat when given together with ixazomib in treating patients with multiple myeloma that has come back or does not respond to treatment. Pevonedistat and ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Smilow Cancer Center/yale-New Haven Hospital

    New Haven, Connecticut, United States

  • Yale University

    New Haven, Connecticut, United States

  • Moffitt Cancer Center

    Tampa, Florida, United States

  • Moffitt Cancer Center - Mckinley Campus

    Tampa, Florida, United States

  • Moffitt Cancer Center-International Plaza

    Tampa, Florida, United States

  • Emory University Hospital/winship Cancer Institute

    Atlanta, Georgia, United States

  • University of Kentucky/markey Cancer Center

    Lexington, Kentucky, United States

  • Duke University Medical Center

    Durham, North Carolina, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ixazomib →Pevonedistat
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
10 Feb 2020
Primary completion
12 Sept 2022
Completion
6 Jul 2023
Last update posted
19 Jun 2025
Registered enrollment
8
Registry id
NCT03770260
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.